Fisher Asset Management LLC Buys 8,012 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Fisher Asset Management LLC raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 124,399 shares of the company’s stock after acquiring an additional 8,012 shares during the period. Fisher Asset Management LLC owned approximately 0.40% of Medpace worth $41,524,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Signaturefd LLC grew its holdings in Medpace by 4.9% during the 2nd quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after purchasing an additional 26 shares during the last quarter. Wealth Alliance boosted its position in shares of Medpace by 2.9% during the second quarter. Wealth Alliance now owns 970 shares of the company’s stock valued at $399,000 after buying an additional 27 shares during the period. Centaurus Financial Inc. grew its stake in shares of Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after buying an additional 29 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Medpace by 0.7% in the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock worth $1,787,000 after buying an additional 32 shares during the period. Finally, Lindenwold Advisors INC lifted its stake in shares of Medpace by 1.6% during the 3rd quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after acquiring an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 0.8 %

Medpace stock opened at $335.21 on Wednesday. The firm has a market cap of $10.42 billion, a P/E ratio of 29.35, a P/E/G ratio of 1.87 and a beta of 1.37. The business has a fifty day moving average of $339.37 and a two-hundred day moving average of $372.21. Medpace Holdings, Inc. has a twelve month low of $268.80 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. During the same period in the prior year, the business posted $2.22 EPS. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. Equities analysts expect that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

MEDP has been the topic of a number of recent analyst reports. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and reduced their target price for the stock from $415.00 to $345.00 in a research note on Wednesday, September 25th. UBS Group cut shares of Medpace from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $420.00 to $350.00 in a research report on Friday, September 27th. William Blair restated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Robert W. Baird boosted their price target on Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a report on Monday. Finally, TD Cowen dropped their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Medpace currently has an average rating of “Hold” and a consensus price target of $380.56.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.